HIMS

29.42

0.48% 0.14

Dopo l'orario di chiusura: 29.34 -0.08 -0.27%

Hims Hers Health Inc (HIMS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HIMS Giù? Forum Previsione

Precedente Chiudi:

$29.28

Aprire:

$29.48

Volume 24 ore:

8.18M

Relative Volume:

0.64

Capitalizzazione di mercato:

$6.86B

Reddito:

$2.35B

Utile/perdita netta:

$128.37M

Rapporto P/E:

56.35

EPS:

0.5221

Flusso di cassa netto:

$57.42M

1 W Prestazione:

+5.11%

1M Prestazione:

-7.34%

6M Prestazione:

+41.17%

1 anno Prestazione:

-46.38%

Intervallo 1D:

$28.57

$29.76

Intervallo di 1 settimana:

$27.31

$31.81

Portata 52W:

$13.74

$65.30

Hims Hers Health Inc Stock (HIMS) Company Profile

Nome

Hims Hers Health Inc

Settore

Healthcare (1067)

Industria

Drug Manufacturers - Specialty & Generic (87)

Telefono

415-851-0195

Indirizzo

2269 CHESTNUT ST, SAN FRANCISCO

Dipendente

2,442

Cinguettio

Prossima data di guadagno

2026-11-02

Ultimi documenti SEC

HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, VTRS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HIMS Hims Hers Health Inc	29.42	6.86B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-24	Iniziato	JP Morgan	Overweight
2026-03-10	Aggiornamento	BofA Securities	Underperform → Neutral
2026-03-10	Aggiornamento	Citigroup	Sell → Neutral
2026-03-09	Aggiornamento	Needham	Hold → Buy
2026-02-24	Downgrade	BTIG Research	Buy → Neutral
2026-01-12	Iniziato	Evercore ISI	In-line
2025-12-09	Iniziato	Barclays	Overweight
2025-10-21	Iniziato	KeyBanc Capital Markets	Sector Weight
2025-06-23	Downgrade	Needham	Buy → Hold
2025-06-04	Reiterato	Needham	Buy
2025-04-29	Downgrade	TD Cowen	Buy → Hold
2025-02-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Downgrade	Citigroup	Neutral → Sell
2025-01-07	Iniziato	BTIG Research	Buy
2024-12-17	Iniziato	Morgan Stanley	Overweight
2024-11-14	Downgrade	BofA Securities	Buy → Underperform
2024-08-22	Iniziato	Needham	Buy
2024-08-09	Downgrade	Imperial Capital	Outperform → In-line
2024-05-22	Downgrade	Citigroup	Buy → Neutral
2024-04-16	Downgrade	Jefferies	Buy → Hold
2024-04-10	Iniziato	Canaccord Genuity	Buy
2024-02-28	Aggiornamento	Imperial Capital	In-line → Outperform
2024-02-26	Iniziato	Leerink Partners	Market Perform
2023-12-07	Iniziato	Imperial Capital	In-line
2023-07-28	Iniziato	TD Cowen	Outperform
2023-04-11	Iniziato	Robert W. Baird	Neutral
2023-02-09	Aggiornamento	Jefferies	Hold → Buy
2022-11-08	Aggiornamento	BofA Securities	Neutral → Buy
2022-11-08	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Downgrade	Piper Sandler	Overweight → Neutral
2022-09-07	Iniziato	Truist	Hold
2022-07-15	Iniziato	SVB Leerink	Underperform
2022-04-14	Iniziato	Guggenheim	Buy
2022-04-01	Ripresa	Credit Suisse	Outperform
2022-03-10	Iniziato	Deutsche Bank	Hold
2021-12-02	Iniziato	Jefferies	Hold
2021-11-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-07-06	Iniziato	BofA Securities	Neutral
2021-05-20	Aggiornamento	Credit Suisse	Neutral → Outperform
2021-04-21	Iniziato	Truist	Hold
2021-03-09	Iniziato	Credit Suisse	Neutral
2021-03-02	Aggiornamento	Citigroup	Neutral → Buy
2021-02-17	Iniziato	Citigroup	Neutral
2021-02-12	Iniziato	Piper Sandler	Neutral
2021-02-08	Iniziato	Tigress Financial	Buy

Mostra tutto

Hims Hers Health Inc Borsa (HIMS) Ultime notizie

05:12 AM

Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform - finance.yahoo.com

05:12 AM

08:12 AM

Shareholders who lost money in shares of acquired Hims & - GlobeNewswire

08:12 AM

Sep 25, 2026

Kaplan Fox Advises Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review

Sep 25, 2026

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - Morningstar

Sep 25, 2026

2 Reasons to Like HIMS (and 1 Not So Much) - finance.yahoo.com

Sep 25, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 25, 2026

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire

Sep 25, 2026

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire Inc.

Sep 25, 2026

HIMS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire

Sep 25, 2026

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 25, 2026

Sep 24, 2026

INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 DeadlineHIMS - TMX Newsfile

Sep 24, 2026

Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation - HIT Consultant

Sep 24, 2026